Abstract: Provided is a microfluidic chip. The microfluidic chip includes a first substrate and a second substrate disposed opposite to each other, a microfluidic channel formed between the first substrate and the second substrate and configured to accommodate at least one droplet, drive electrodes arranged in an array and sensing electrodes disposed on a side of the first substrate. Each sensing electrode includes at least one first branch electrode and at least one second branch electrode. The first branch electrode extends along a first direction, and the second branch electrode extends along a second direction. Different drive voltage signals are applied to adjacent drive electrodes to drive the droplet to move. Detection signals are applied to the sensing electrodes, and a position of the droplet is determined according to a change in capacitance between one sensing electrode and an electrode corresponding thereto when the droplet flows by.

Abstract: Methods, systems, and apparatus, including an apparatus for managing user data according to user consent settings are described. In some aspects, a method includes determining that a request for transmission by a client device to a recipient will include user data of a user of the client device. In response determining that the request will include the user data, the method includes requesting, from a consent management module of the client device, current user consent settings specified by the user which define at least one of (i) user data that can be transmitted from the client device, (ii) how user data transmitted from the client device can be used or (iii) which recipients can receive and retain user data from the client device. The method further includes receiving, from the consent management module, the current user consent settings and generating request data according the current user consent settings.

Abstract: The present invention provides novel gene signature associated with immune checkpoint inhibitor (ICT) named ImmuneCells.Sig which is predicative of ICT outcomes of melanoma patients which is significantly more accurate than all previously reported ICT response signatures. The ImmuneCells.Sig can be used as an accurate predictor of ICT response and may be used to determine if a patient will be susceptible and respond to ICT treatment.

Abstract: In accordance with an embodiment of the present invention, a resistive switching device includes an opening disposed within a first dielectric layer, a conductive barrier layer disposed on sidewalls of the opening, a fill material including an inert material filling the opening. A solid electrolyte layer is disposed over the opening. The solid electrolyte contacts the fill material but not the conductive barrier layer. A top electrode is disposed over the solid electrolyte.

Abstract: Methods for inhibiting proliferation of a cell, particularly a cancer cell are provided. The method comprises increasing intracellular levels of one or more wild-type ras proteins in the cell. In one aspect, the method comprises introducing and expressing a nucleic molecule that encodes a wild-type ras protein in the cell. In another aspect, intracellular levels of one more ras proteins are increased by introducing one or more wild-type ras proteins into the cell. The present invention also relates to the therapeutic use of wild-type ras proteins or nucleic acids that encode one or more wild-type ras proteins in the treatment of tumors or cancer, or prophylactically to prevent formation of tumors or cancer. Methods of characterizing or evaluating cancer in a humans or other mammals are provided. In one embodiment, the method comprises assaying for a loss of function mutation in one or more endogenous ras alleles in the genome of tumor cells obtained from the subject.